CMML Diagnosis via CD14/CD16 Monocyte Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Chronic Myelomonocytic Leukemia (CMML) are time-consuming, prone to misidentification, and lack specificity, relying on multiple criteria that are difficult to apply in clinical practice.
Innovation Solution
A method utilizing flow cytometry to quantify CD14+/CD16- monocytes in a blood sample, providing a rapid and specific diagnostic criterion for CMML by comparing the proportion of these monocytes to a reference value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current WHO criteria are used for CMML diagnosis, then diagnostic coverage is achieved, but diagnostic time increases and accuracy decreases due to multiple complex criteria
Solution Approach 1:
The patent extracts a single critical diagnostic criterion (CD14+/CD16- monocyte proportion) from the complex WHO criteria system. By focusing on this specific cell population marker, the method isolates the most discriminatory feature for CMML diagnosis, eliminating the need to evaluate multiple overlapping criteria and thereby reducing diagnostic time while maintaining or improving accuracy.
Solution Approach 2:
The patent changes the diagnostic parameter from composite clinical criteria to a specific immunophenotypic parameter (CD14/CD16 expression profile). This parameter transformation enables quantitative flow cytometry measurement, providing an objective, rapid, and precise diagnostic metric that resolves the trade-off between comprehensive evaluation and diagnostic efficiency.
2Reliability
If multiple WHO criteria are applied for CMML diagnosis, then diagnostic coverage is maintained, but ease of operation decreases due to complex application requirements
Solution Approach 1:
The patent segments the complex diagnostic process into a single focused measurement: quantifying CD14+/CD16- monocytes. This segmentation simplifies the operational workflow while maintaining diagnostic reliability by concentrating on the most discriminative feature, making the diagnosis more accessible to clinical practitioners.
Solution Approach 2:
The patent replaces manual evaluation of multiple clinical criteria with automated flow cytometry analysis. This substitution of mechanical/manual assessment with instrument-based quantitative measurement improves both ease of operation and objective reliability, as the flow cytometer automatically calculates the proportion of diagnostic cell populations.
3Productivity
If conventional diagnostic methods are used, then comprehensive evaluation is achieved, but measurement precision decreases due to misidentification risks
Solution Approach 1:
The patent introduces CD14 and CD16 surface markers as intermediary indicators for CMML diagnosis. These markers serve as reliable mediators that objectively indicate disease presence, eliminating subjective interpretation and misidentification risks associated with conventional clinical criteria evaluation.
Solution Approach 2:
The patent utilizes flow cytometry-based fluorescent labeling of CD14 and CD16 markers, where different fluorochrome emissions indicate distinct monocyte subsets. This optical differentiation enables precise identification and quantification of diagnostic cell populations, dramatically improving measurement specificity compared to conventional morphology-based methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, accurate, and confident diagnosis of CMML with high sensitivity and specificity, distinguishing it from other blood diseases within 24 hours, improving upon the limitations of existing diagnostic criteria.
Implementation Method 1
Detecting by flow cytometry a monocyte population
Implementation Method 2
quantifying by flow cytometry the monocytes expressing CD14 but not expressing CD16
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The present invention relates to an in vitro method of diagnosing chronic myelomonocytic leukemia (CMML) in a subject, said method comprising the steps of: a) Detecting a monocyte population in a biological sample from said subject; b) Quantifying the CD14+/CD16- monocytes in said biological sample; c) Comparing the value of step b) to a reference value; and d) Diagnosing CMML based on said comparison. Preferably, said detecting step a) is performed by an exclusion gating strategy by flow cytometry.